Pharmacokinetic/pharmacodynamic models for the depletion of Vβ5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS

British Journal of Clinical Pharmacology

Volumn 58, Issue 4, 2004, Pages 378-389

  Zingmark, Per Henrik ^a,c   Edenius, Charlotte ^b   Karlsson, Mats O ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b Biolipox AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Clinical trial simulations; FACS; Logistic regression; Monoclonal antibody; Non linear mixed effects models; Pharmacodynamics; Pharmacokinetics; Proportional odds model

Indexed keywords

ATM 027; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MODEL; MULTIPLE SCLEROSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DENSITY; SIMULATION; T LYMPHOCYTE;

ADULT; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MODELS, CHEMICAL; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 4744360901     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02177.x     Document Type: Article

References (16)

1. Klareskog L, Olsson T. Autoimmunity to collagen II and myelin basic protein. Comparative studies between man and rodents, Immunol Rev 1990; 118: 285-310.
2. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyellinating diseases. Annu Rev Immunol 1992; 10: 153-87.
3. Olsson T, Edenius C, Ferm M, Samuelsson P, Torrång A, Wallström E, Khademi M, Andersson M, Årfors L. Depletion of Vβ5.2/5.3 T cells with a humanized antibody in patients with multiple sclerosis. Eur J Neurol 2002; 9: 153-64.
4. Killestein J, Olsson T, Wallström E, Svenningsson A, Khademi M, Blumhardt LD, Fagius J, Hillert J, Landtblom AM, Edenius C, Årfors L, Barkhof F, Polman CH. Antibody-mediated suppression of Vβ5.2/5.3 T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. Ann Neurol 2002; 51: 467-74.
5. Beal SL, Sheiner LB. NONMEM User Guides. University of California, San Fransisco, CA: NONMEM Project Group, 1992.
6. Jonsson EN, Karlsson MO. Xpose - an S-PLUS population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comp Meth Prog Med 1999; 58: 51-64.
7. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-71.
8. Sheiner LB. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther 1994; 56 (3): 309-22.
9. Magee MH, Blum RA, Lates CD, Jusko WJ. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 2001; 41 (11): 1180-94.
10. Schuler M, Peschel C, Schneller F, Fichtner J, Farber L, Huber C, Aulitzky WE. Immunomodulatory and hematopoetic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer. J Interferon Cytokine Res 1996; 16 (11): 903-10.
11. Anderson PM, Katsanis E, Sencer SF, Hasz D, Ochoa AC, Bostrom B. Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. J Immunother 1992; 12 (1): 19-31.
12. Mould DR, Davis CB, Minthorn EA, Kwok DC, Elliott MJ, Luggen ME, Totoritis MC. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin Pharmacol Ther 1999; 66: 246-57.
13. Tanswell T, Garin-Chesa P, Rettig WJ, Welt S, Divgi CR, Casper ES, Finn RD, Larson SM, Old LJ, Scott AM. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. Br J Clin Pharmacol 2001; 51: 177-80.
14. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokin Biopharm 1999; 27 (4): 397-420.
15. Kovarik JM, Nashan B, Neuhaus P, Clavien P-A, Gerbeau C, Hall ML. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin Pharamcol Ther 2001; 69: 201-9.
16. He Magee M, Blum RA, Lates CD, Jusko WJ. Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. Br J Clin Pharmacol 2002; 53: 474-84.